Recent corporate updates from Larimar Therapeutics center on the clinical advancement and regulatory pathway of nomlabofusp, its experimental therapy for Friedreich's ataxia. Following constructive feedback and Breakthrough Therapy Designation from the FDA, the company commenced a rolling BLA submission seeking accelerated approval. Additionally, encouraging open-label study data revealed sustained frataxin level improvements, while successful capital-raising efforts ensured strong financial liquidity to support upcoming global Phase 3 confirmatory studies.